T2DM & IR

Getting your Trinity Audio player ready...
Insulin Resistance & Type 2 Diabetes — USA & UK 1975–2022

Insulin Resistance & Type 2 Diabetes

Prevalence trajectories in the USA and United Kingdom, 1975–2022. Type 2 diabetes is the most direct downstream consequence of insulin resistance — the right axis shows diagnosed T2DM, representing the late-stage outcome of the same metabolic process measured on the left axis.

United States

USA — Insulin Resistance vs T2DM

1975 – 2022  |  % of population
Insulin Resistance
T2DM Diagnosed
United Kingdom

UK — Insulin Resistance vs T2DM

1975 – 2022  |  % of population
Insulin Resistance
T2DM Diagnosed
r = 0.98
USA
IR ↔ T2DM
r = 0.97
UK
IR ↔ T2DM
+400%
USA T2DM rise
1975 – 2022
+350%
UK T2DM rise
1975 – 2022
The defining relationship: T2DM is the clinical end-stage of insulin resistance. HOMA-IR scores above approximately 2.5 indicate clinically significant insulin resistance; once beta-cell exhaustion follows, diagnosed T2DM results. The r values here (0.97–0.98) approach the maximum possible for ecological data, because these two measures are not merely correlated — they are sequential stages of the same physiological process. A HOMA-IR test will typically detect insulin resistance 10–20 years before T2DM diagnosis — the critical reversible window that conventional medicine largely misses.
What is r?  Pearson correlation coefficient. 0 = no relationship  |  1.0 = perfect parallel rise. Above 0.7 = strong. These are population-level — association, not cause.
Data sources
T2DM USA: CDC National Diabetes Statistics Report 1980–2022; NHANES 1999–2020; Geiss et al. JAMA 2014. Age-adjusted diagnosed diabetes prevalence: ~1.0% (1975) → 2.2% (1990) → 4.5% (2000) → 6.4% (2010) → 7.4% (2022). Undiagnosed cases add an estimated further 25%.
https://www.cdc.gov/diabetes/php/data-research/index.html
https://jamanetwork.com/journals/jama/fullarticle/1835948
T2DM UK: Diabetes UK State of the Nation reports 2010–2022; NHS Digital National Diabetes Audit 2003–2022; Health Survey England. UK prevalence: ~1.2% (1975) → 3.5% (2000) → 7.0% (2022). ~4.3 million diagnosed in UK 2022, ~90% T2DM.
https://www.diabetesuk.org/professionals/position-statements-reports/statistics/
https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit
Insulin Resistance USA: NHANES III 1988–94; NHANES 1999–2018 (Hirode & Wong, JAMA 2020); Frontiers meta-analysis 2025.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11601873/
https://pmc.ncbi.nlm.nih.gov/articles/PMC12411212/
Scroll to Top
MENU
For Radiant Health